VivaVision to advance non-steroidal therapy in Phase III following Phase II win
China-headquartered VivaVision Biotech is looking to advance its non-steroidal therapy, VVN461-CS-201 (VVN461), in a Phase III trial after the candidate…
Ophthalmology
-
-
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial
Outlook Therapeutics’ second attempt to obtain US approval for its wet age-related macular degeneration (wet AMD) therapy, Lytenava (bevacizumab-vikg) has…
-
Glaukos eyes FDA approval for ocular therapy after Phase III win
Glaukos plans to file for US approval of its iLink corneal cross-linking therapy Epioxa (Epi-on) for treating keratoconus after the…
-
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints
Viridian Therapeutics’s veligrotug has met all primary and secondary endpoints in a Phase III trial in active thyroid eye disease…
-
Boehringer and CDR-Life report data from geographic atrophy treatment trial
Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new treatment…
-
MSD and EyeBio launch trial of Restoret for diabetic macular oedema
MSD (Merck & Co) and its wholly-owned subsidiary EyeBio have announced the start of the Phase IIb/III BRUNELLO clinical trial…
-
FDA approves BlueRock’s cell therapy IND for photoreceptor diseases trial
The US Food and Drug Administration (FDA) has granted clearance for BlueRock Therapeutics’ investigational new drug (IND) application to commence…
-
FDA grants IND clearance for Find’s Phase I chronic optic neuropathy trial
The US Food and Drug Administration (FDA) has granted clearance for Find Therapeutics' investigational new drug (IND) application to commence…
-
Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint
Aldeyra Therapeutics has met the primary endpoint in a Phase III clinical trial of the Reproxalap drug for dry eye…
-
Viridian completes subject enrolment for Phase III trial of TED treatment
Viridian Therapeutics has announced the completion of subject enrolment for its Phase III THRIVE-2 clinical trial of VRDN-001, aimed at…
